Pulling back from the brink
The US healthcare reform bill raises as many questions as it answers for Big Pharma
For the pharmaceutical industry, the bill is a bit of a mixed bag, although the general impression at the moment is that manufacturers will gain more than they lose. At the very least some of the uncertainty affecting the sector has been removed.
With an extra 32 million potential patients entering the market, the number of prescriptions is bound to rise, but this is likely to be offset by the imposition of higher discounts and rebates. And with a number of significant patents due to expire in 2011, a short-term downturn for the industry seems inevitable, although these negative effects should be offset by rising revenues from increased drug consumption by around 2015, according to Datamonitor.
But as drug costs rise, the US government is bound to want to make sure it is getting the best possible value for its money and will increase its involvement in the healthcare sector. While this will be good news for the manufacturers of generic medicines, the authorities will need to try to avoid some of the less palatable aspects of the UK system – trying to define ‘quality of life’, and the notorious ‘postcode prescribing’.
From a European point of view, the US system was patently unfair and long overdue for reform. However imperfect the various healthcare regimes are in the EU, there is at least always a safety net to ensure that every citizen is entitled to receive at least a basic level of service.
It is hard to comprehend the strenuous efforts mounted – both by opposition politicians and the general public – to defend a system that excludes more than 32 million people and where a patient who survives cancer is essentially ruled out of any future treatment by a massive rise in premiums that put them beyond the reach of those on an average income. Shockingly, half of all personal bankruptcies in the US are at least partially due to medical costs.
The reforms may still be flawed, but at least those outside the current system dangling by a thin rope and staring into the abyss have been thrown a lifeline.
Hilary Ayshford
Editor
You may also like
Trending Articles
You may also like
Finance
hVIVO’s CRS secures more than £5m in early-phase clinical trial contracts to strengthen 2026 pipeline
hVIVO’s German subsidiary CRS has signed more than £5 million in early-phase clinical trial contracts across cardiometabolic, dermatology, infectious disease, renal and oncology, bolstering its 2026 orderbook and highlighting the growing cross-selling benefits across the Group
Regulatory
BCMPA warns Chancellor: avoid new tax burdens on SMEs in upcoming Budget
The BCMPA is urging the UK Government to ease pressure on small manufacturers by reducing National Insurance costs, cutting red tape and considering SME impact assessments, warning that rising costs and uncertainty are stalling investment and growth
Finance
Sofinnova Partners closes €650m ($750m) Capital XI fund to boost early-stage biotech investment across Europe and the US
Sofinnova Partners has closed its flagship Capital XI fund at €650m, surpassing its target. The Paris-based firm will use the fund to advance early-stage biotech and medtech companies in Europe and North America